J0582 HCPCS Level II code: Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg
J0582 is the HCPCS code for “Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J0582Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg
Short description: Bivalirudin (endo) 1 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J0582 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Oct 1, 2025
Where J0582 sits
- 1J codesDrugs administered other than orally
- 2Active code J0582Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J0582 mean?
J0582 is the HCPCS code for “Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J0582?
CMS lists J0582’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J0582
All J codesJ0573Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphineJ0574Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphineJ0575Buprenorphine/naloxone, oral, greater than 10 mg buprenorphineJ0576Injection, buprenorphine extended-release (brixadi), 1 mgJ0577Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapyJ0578Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapyJ0583Injection, bivalirudin, 1 mgJ0584Injection, burosumab-twza 1 mgJ0585Injection, onabotulinumtoxina, 1 unitJ0586Injection, abobotulinumtoxina, 5 unitsJ0587Injection, rimabotulinumtoxinb, 100 unitsJ0588Injection, incobotulinumtoxin a, 1 unit